Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

The recruitment status of this study is unknown because the information has not been verified recently.

Verified August 2003 by National Institute on Drug Abuse (NIDA). Recruitment status was Active, not recruiting

First Received on June 18, 2002. Last Updated on February 8, 2007 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of California, Los Angeles
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00040040

Purpose

The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.

Condition	Intervention	Phase
Amphetamine-Related Disorders	Drug: Bupropion	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Masking: Double-Blind Primary Purpose: Diagnostic
Official Title:	Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion

Resource links provided by NLM:

MedlinePlus related topics: Drug Reactions Methamphetamine

Drug Information available for: Methamphetamine hydrochloride Bupropion hydrochloride Bupropion Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Psychological effects
BP, HR

Estimated Enrollment:	20
Study Start Date:	June 2002
Estimated Study Completion Date:	September 2003

Detailed Description:

This is a human laboratory clinical pharmacology study to assess potential interactions between IV methamphetamine challenge and treatment with oral sustained-release bupropion.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Please contact site director for more details.

Exclusion Criteria:

Please contact site director for more details.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040040

Locations

United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, Texas
University of Texas Health Science Center
Houston, Texas, United States, 77225

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of California, Los Angeles

Investigators

Principal Investigator:

Thomas Newton, M.D.

National Institute on Drug Abuse (NIDA)

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00040040 History of Changes
Other Study ID Numbers:	NIDA-CTO-0010-1
Study First Received:	June 18, 2002
Last Updated:	February 8, 2007
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Amphetamine-Related Disorders
Substance-Related Disorders
Mental Disorders
Methamphetamine
Amphetamine
Bupropion
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dopamine Agents

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs

ClinicalTrials.gov processed this record on February 12, 2012